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4ABSTRACT
This thesis reports the development of potent and selective inhibitors of m-calpain for the 
treatment of cataract. 
SJA6017 has been proven to prevent lens opacity in rat and has been our lead compound. 
A series of Val-Leu peptidyl aldehyde inhibitors (33a-e, 33g, 33i and 35) have been 
designed, synthesized, and tested for therapeutic potential as cataract inhibitors.    
  
Chapter 1 is an introduction to calpain and the diseases associated with it’s over 
activation. A review of the literature on calpain inhibition is given. Structure activity 
relationship (SAR) theory is presented. The techniques that have been applied in our 
research group to drug design include molecular modeling, synthesis, assay and animal 
studies which are all briefly discussed. The importance of a -strand conformation for an 
inhibitor to bind to calpain is discussed.  
Chapter 2 describes the synthesis of m-calpain inhibitors. This comprises the preparation 
of the Val-Leu dipeptide core 29, Val-Leu dipeptidyl alcohols 31a-g and 31i, and the 
synthesis of dipeptidyl aldehydes 33a-e, 33g, 33i and 35. The choice of coupling regents 
and conditions in the coupling reactions is investigated. Sulfur trioxide pyridine oxidation 
for the conversion of Val-Leu dipeptidyl alcohols to aldehydes is discussed. The 
molecular modeling and biological assay results are presented.  
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7Chapter 1: Introduction 
1.1: Calpain Structure  
Proteases are the enzymes that catalyze the cleavage of target proteins into smaller 
peptide fragments and amino acids. Peptide hydrolysis depends on key catalytic residues 
and as such proteases have been classified into serine, threonine, cysteine, aspartic acid, 
metallo, and glutamic acid proteases.  
Molecular biological studies have shown that calpains are calcium-dependent cysteine 
proteases. There are two major calpain isoforms, known as calpain I (-calpain) and 
calpain II (m-calpain). They have the same substrate specificity and both subunits contain 
multiple Ca2+ binding EF-hands. They differ in the Ca2+ concentration requirement for 
activation.1 Calpain I requires a micromolar concentration of Ca2+ (1-100 M) whereas 
calpain II is activated by millimolar concentration of Ca2+ (0.1-1 mM).2  
Calpain contains a large catalytic subunit (80-kDa) and a small regulatory subunit 
(30-kD). The typical large subunit of calpain is composed of four domains (I–IV) and the 
small subunit of calpain has at least two domains (V and VI). Ca2+ binds at the sites of 
two calmodulin-like domains IV and VI, an acidic loop region in domain III, and the 
protease domain II (Figure 1). Ca2+ binding releases the constraints imposed by domain 
interactions, and rearranges the active site cleft to form a functional catalytic site.3
8Figure 1: Three-dimensional structure of human m-calpain without Ca2+ bound.4
Recent X-ray structures of mini - and m-calpain constructs has revealed the 
Ca2+-induced activation mechanism at the molecular level.5 A crystal structure of human 
m-calpain in an un-activated form was obtained (Figure 2A). This structure revealed that 
without calcium bound the distance between sulfur of Cys105 and the imidazole nitrogen 
of His262 of the catalytic triad is 8.5 Å. It was not possible to get an X-ray crystal 
structure of an activated calpain, as calpain is autolytic, therefore site directed 
mutagenesis was used to convert Cys115 to Ser115. The crystal structure of a calcium 
bound mini µ-calpain mutant construct revealed the distance between oxygen of Ser115
9and the imidazole nitrogen of His272 is 3.7 Å (Figure 2B). This conformational change of 
the catalytic triad “cysteine-histidine-asparagine” leads to activated calpain which can 
catalyze the cleavage of amide linkages in calpain substrates. 
     

Figure 2: X-ray crystal structures of A) An un-activated m-calpain construct. B) An 
activated µ-calpain (Cys115 to Ser115) construct.
To catalyze the hydrolysis of the peptide bonds, calpain firstly acts as a surface that binds 
the substrate to the active site. Calpain subsites bind the peptide chain on either side of 
the scissile peptide bond and show specificity for particular side chains.3 The binding 
between the enzyme and substrate is determined by the electrostatic character and the 
size of the enzyme subsites. Binding of a substrate is designated using the standard 
nomenclature developed by Berger and Schechter (Figure 3).6
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Figure 3: Amino acid residues and subsites from enzyme are denoted by P1, P2 and the S1, 
S2 etc towards the amino side of peptide from catalytic site. The carboxyl side of the 
peptide and corresponding subsites are termed P1’, P2’, Pn’ and S1’, S2’and Sn’, 
respectively. 
1.2: Mechanism of calpain activation  
The crystal structure of m-calpain without calcium bound is illustrated and the active site 
(domain II) and Ca2+ bonding sites (domains IV, VI) are shown in Figure 1. 
Conformations of the catalytic triad in active and inactive states of calpain are shown in 
Figure 2. The conformational change on bonding of calcium lowers the activation energy 
for the substrate hydrolysis and the structure-based mechanism has been thereby 
proposed.7 
To catalyze the hydrolysis of peptide bonds, the first step is deprotonation of a thiol in the 
active site of calpain by a histidine residue of an adjacent amino acid. The next step is 
nucleophilic attack by the activated cysteine's anionic sulfur on the substrate carbonyl 
carbon to form thioester intermediate. A fragment of the substrate is released having an 
amine terminus. The thioester bond is hydrolyzed to generate a carboxylic acid and 
11
regenerates the free enzyme (Scheme 1).  
        
Scheme 1: The mechanism of action of cysteine proteases. 
Calpains can cleave a large number of substrates and show specificity for bonding of the 
amino acid neighboring the cleavage site. Cleavage occurs frequently at the C-terminal 
side (P1 position) of tyrosine, methionine, or arginine, next to leucine or valine (P2
position).8
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1.3: Calpain and Disease 
The overactivation of calpain has been observed in several medicine conditions such as 
Alzheimer’s, 9 , 10  Huntington’s, Parkinson’s diseases,11  ischemic and traumatic brain 
injury,12 cancer, Muscular Dystrophy, strokes, diabetes and cataract.13 (Table 1)  
Calpain Diseases 
Calpain 1 stroke, traumatic brain injury, Alzheimer’s disease, cataracts 
Calpain 2 stroke, traumatic brain injury, Alzheimer’s disease, cataracts 
Calpain 3 Limb-girdle muscular dystrophy 2A, cataracts 
Calpain 9 gastric cancer 
Calpain 8/10 Type 2 diabetes mellitus 
  
Table 1: Calpain family and various pathological conditions.14
The over activation of calpain I can cleave and activate calcineurin. Calcineurin (CaN) is 
known as protein phosphatase (PP)2B. The phosphatase activity of CaN is regulated by 
Ca2+/calmodulin and calpain activation. The activation of calcineurin is related to the 
number of neurofibrillary tangles in human brains and hence mediates the role of calcium 
homeostatic disturbance in the neurodegeneration of Alzheimer’s disease.15
Huntington’s disease has also been correlated with the calpain activity. The activated 
calpain catalyzes the hydrolysis of the Huntington protein at multiple sites and the 
resulting toxic protein fragments are responsible for neuronal loss leading to 
Huntington’s disease.16  
13
A substrate for calpain called -synuclein is the major component of lewy bodies (LBs). 
LBs are hallmark lesions of degenerating neurons in the brains which can lead to 
Parkinson's disease (PD).17  
Loss-of-function mutations of the calpain 3 gene have been identified as the cause of 
limb-girdle muscular dystrophy 2A.  
Elevated calpain 5 levels have been correlated with polycystic ovary syndrome (PCOS), 
obesity, hypertension and dyslipidemia.18  
1.4: Origin of cataract and its treatment  
The lens of the human eye is located in the anterior segment and is a highly specialized 
non-vascular tissue. The lens focuses an image onto the retina of the eye, converting light 
energy into an electrical impulse. The impulses are then interpreted by the brain as vision 
(Figure 4). Cataract is a disease of the eye that results in the lens becoming opaque and 
thereby distorting light as it passes through the lens. The opacification of the lens prevent 
the light from reaching the retina resulting in a decrease in the quality of vision and 
ultimately in blindness. 
14
        
Figure 4: The way the human eye works.19
Cataract formation results from a variety of insults such as genotype, selenite and damage 
from ultraviolet light. Research on selected age cohorts of normal human subjects has 
shown that, on average, as the human lens ages, the intensity of light scattered backwards 
out of the pupil increases exponentially with age.20
The ageing process or other insults lead to impaired membrane function, which results in 
elevated levels of Ca2+ in the lens tissue. Under these conditions, calpains are 
overactivated and the resulting deregulated proteolysis of soluble crystallins leads to their 
insolubilization and aggregation. This compromises the function of crystallins in 
maintaining lens transparency and produces the reduced lens performance associated with 
cataract (Figure 5).21 Thus, calpain activity is important and the development of calpain 
inhibitors could interfere with cataract progression.  
15
Figure 5: Calpain dependent cataract.22  
Currently the only treatment for cataract is surgery. The lens of the eye that has developed 
a cataract is removed and replaced with an artificial intraocular lens.23 This is a safe and 
successful procedure for cataract treatment. However, the expensive cost of surgery and 
long waiting lists along with fear of surgery especially for the elderly impede this 
treatment. An alternative treatment to reduce the urgency for replace surgery is needed.24
The medical treatment of cataract is one of the most important challenges in ophthalmic 
research.25 Inhibitor E64 and its analogues have been developed and tested as the 
anti-cataract agents. 26  They are the epoxysuccinyl peptides and have electrophilic 
warheads that can interact with the active site of calpain irreversibly. However, because 
of their poor selectivity for calpains and cell impermeability, E64 has been established as 
unsuitable for development.
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SJA6017 has been synthesized by Senju pharmaceutical and proved to be effective 
against selenite-induced cataract in rat.27 Much work has been done in our research 
group to increase the potency, selectivity, and bioactivity of the lead inhibitor SJA6017. 
The first generation cataract inhibitors developed in the Abell/Coxon laboratory have an 
aldehyde warhead and a Val-Leu dipeptide core (Figure 6).  
H
N
N
H
O
CHO
Additional Recognition
Figure 6: The first generation cataract inhibitors.
To increase the potency, cell permeability, water solubility, one strategy is to alter the left 
hand side (additional recognition). To date some 100 compounds of this type have been 
synthesized in our laboratory and assayed as inhibitors of calpain. These compounds are 
regarded as the first generation calpain inhibitors and have open chain structures. The 
compounds displaying nanomolar m-calpain inhibition constants (IC50) that have 
comparable potency to SJA6017 are shown in Figure 7. 
17
H
N
S
O
N
HO O
N
N
O
H
H
N
O
N
H
OO
O
N
H
H
N
O
N
H
OO
O H
H
N
S
O
N
H
O
O O
F
H
0002-Shkeru Miyamoto0003-Richard Payne
0066-Janna NikkleSJA 6017
H
N
O
N
H
O
S
H
N
N
N
OO
0087-Matt Jones
H
N
S
O
N
H
O
O O
S
H
0078-Matt Jones
Figure 7: Nanomolar m-calpain inhibitors synthesised by the Abell/ Coxon research 
group. 
To increase the biostability, -amino acids can be introduced into peptide-based drugs 
since these compounds cannot be recognised by protease as being of peptide origin and 
thus remain stable in metabolism. A series of novel SJA6017 analogues were developed 
in our research group in an attempt to increase biostability.28 This can be achieved by 
replacing the Val, Leu residues with the corresponding -amino acids. However the 
inhibitor potency of these compounds was significantly lower.
18
1.5: The importance of a -strand conformation for calpain inhibitors 
The structure and conformation of an inhibitor plays an important role in its biological 
activity. This is because calpains can only recognize particular side chains and backbones 
and the interaction of inhibitor and calpain must present an entropy advantage. However 
most peptidic inhibitors are conformationally flexible and must present in a bioactive 
conformation before being recognized and bound by calpains. A kinetic study of 
protease-inhibitor complex formation (Figure 8) shows that inhibitor in a random 
conformation (Iinact) must convert to the active conformation (Iact) which is then bound by 
the enzyme to form the enzyme-inhibitor complex.  
Calpain inhibitors should be designed such that the bioactive conformation is well 
populated thereby minimizing entropy loss on enzyme-inhibitor bonding.  
I inact I act E.I
Kx
K-x
E
K1
K -1
Figure 8: Conformational pre-equilibria of inhibitors and formation of protease inhibitor 
complex. I inact / I act is the inhibitor in inactive/active conformation.29
The -strand conformation has potential in calpain inhibitor design. Fairlie et al. studied 
more than 1500 three dimensional X-ray structures of proteases in the Protein Data Bank 
and concluded that proteases universally bind the ligands in a -strand conformation 
(Figure 9a). 30  This conformation prevents intramolecular hydrogen bonds of the 
adjacent amide bonds and optimizes the location of side chain residues for better bonding 
19
to the proteases. The -strand structure can be defined by bond angles , , and  with 
optimum angles of -120°, 120° and 180° respectively (Figure 9b).
      
                 (a)                                    (b) 
Figure 9: (a) 3D structure of -strand conformation; (b) -strand backbone with torsional 
angles.  
Population of a -strand conformation is formed as the result of an extensive hydrogen 
bonding network and favorable side chain-side chain interactions. The residues in this 
conformation can be located at a right angle to the extended structure and thereby 
minimize steric interactions. The reason a ligand/inhibitor adopts such conformation is 
mainly due to the reduced loss of entropy for bonding. 
For most of potent calpain inhibitors, three hydrogen bonds exist between inhibitor and 
Gly208 and Gly271 residues and the side chain functional groups must be in a specific 
arrangement to give rise to the -strand geometry. 
20
1.6: Literature Review of Calpain Inhibitors 
Calpain inhibitors can be found in nature through screening, isolation, purification, and 
structure determination. Compound 1 was extracted from a streptomyces species and has 
been reported to inhibit calpain I and calpain II with Ki values of 36 nM and 50 nM 
respectively, however this compound is not selective for calpain and can also inhibit 
trypsin, chemotrypsin and cathepsin H.31 Damnacanthal 2 was isolated from the root of 
Morinda citrifolia and is an effective calpain inhibitor; however, this compound has a 
poor selectivity since it inhibits other cysteine proteases.32 Leupeptin 3 is the most 
widely known inhibitor and was isolated from streptomyces, however it displays no 
selectivity for calpain and the polarity of the arginine residue leads to the poor cell 
permeability (Figure 10).33
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Figure 10: Typical calpain inhibitors from natural extraction. 
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Natural calpain inhibitors have limited potential for drug development because of their 
poor stability, solubility, selectivity and bioavailability. Therefore these inhibitor leads 
must be modified to have potential as therapeutic agents.  
Synthetic calpain inhibitors can be divided into peptidic and non-peptidic compounds. 
The peptidic inhibitors consist of an address region for the enzyme recognition, namely a 
peptidic backbone that interacts with S1 and S2 subsites on calpain surface, and a warhead 
which can form a covalent bond either reversibly or irreversibly with the thiol group (-SH) 
of the active site of calpain.  
The structures of two representative mercaptoacrylic acids 4, 5 (shown in Figure 11) have 
the free thiol, carboxylate group and double bonds binding to the Ca2+ binding site.34 
I
CO2H
SH
                 
H
N
CO2H
SH
F
4 5
Figure 11: Non-peptidic calpain inhibitors. 
Synthetic peptidic calpain inhibitors are classified into reversible (e.g. peptidyl aldehydes 
and peptidyl α-ketoamides) and irreversible inhibitors (e.g. peptidyl epoxides and 
β-fluoro ketones).35
22
Irreversible calpain inhibitors react with the Cys residue in the active site to form a 
permanent covalent bond. Examples of these include peptide epoxide inhibitors, 
azapeptides, and peptide acyloxymethyl. Because of the ubiquitous distribution of calpain 
isoforms, non-selective irreversible inhibitors have serious side effects.  
Reversible inhibitors are preferable since they react with the enzyme’s active site to form 
a stable but reversible species such as tetrahedral thiohemiacetal adduct. These adducts 
can resemble the transition states for substrate hydrolysis and thereby function as 
competitive inhibitors. Examples of reversible transition state inhibitors are peptide 
aldehydes,36,37 α-diketones,38 α-ketoesters, α-ketoamides and α-ketoacids.39
Classical peptidic calpain inhibitors are generally designed by replacing the scissile 
amide bond of calpain substrates with an electron deficient center (the warhead) (Figure 
12). The electron deficient center is usually an electrophilic carbonyl containing 
functional group (such as an aldehyde or a ketone) that can form a covalent bond either 
reversibly or irreversibly with the thiol group (-SH) of the active site Cys105 (m-calpain) 
or Cys115 (-calpain).  
A peptidic calpain inhibitor has a peptidic backbone that interacts with S1 and S2 subsites 
on the calpain surface. Structure activity relationship (SAR) studies show that valine is 
preferable at the P2 position, and the S1 subsite of calpain can accommodate large 
hydrophobic groups from the P1 position of inhibitors.
40 An aromatic group at N-terminal 
capping position seems to be favorable for binding to the S3 subsites for the enzyme 
recognition (Figure 12).8
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Figure 12: Design of peptidic calpain inhibitors. 
A recent study of some 20 inhibitors including the measurement of IC50 values has been 
reported by Senju pharmacy Co Ltd. The IC50 values of these inhibitors containing an 
aldehyde warhead range from 7.5 to 630 nM, with the most potential being N- 
(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (6, SJA6017) (Figure 13). Compound 6 was 
10 times more potent against -calpain and twice as potent against m-calpain as any other 
calpain inhibitors tested. The synthetic calpain inhibitor 6 and its derivates can ameliorate 
cataractogenesis and diminish lens opacity in rats and porcine cataract models. However, 
this compound has poor membrane permeability, and bind to plasma proteins.  
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Figure 13: Structure of synthetic calpain inhibitor 6 (Senju Pharmaceuticals). 
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Compound 6 is a lead compound and structure activity relationship studies of analogous 
compounds were carried out by Senju Pharmaceuticals. A considerable amount of work 
to try to optimize a drug was reported but to date no compound has been tested in a 
clinical trial.   
To improve the metabolic stability, Senju Pharmaceuticals prepared the cyclic hemiacetal 
7, nitrile 8, and R-ketoamide 9 (Figure 14) and evaluated them as calpain inhibitors.41 In 
this series, the aldehyde has been replaced because of its high activity which reacts 
superfluously with various substrates under physiological conditions. The hemiacetal 7 
shows the most stability and has good water solubility, but is less potent than compound 
6. 
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Solubility is important since only compounds in solution are able to permeate across the
cornea barrier.42 To increase the water solubility alternative warheads were examined. 
Senju Pharmaceuticals examined peptidyl nitriles (8), α-ketoamides (9) and peptidyl 
hydrazones (11).43 The hydrazone was a new template for calpain inhibition with 
N,N-dimethyl glycyl hydrazone 11 having appropriate water-solubility and being a potent 
inhibitor. Another way to increase the water-solubility was by incorporation of a pyridine 
ring at the P3 site (10) but this compound exhibited only moderate activity.44
A series of 6-hydroxy-3-morpholinones has also been developed in which the aldehyde 
function group was converted to a cyclic hemiacetal (Figure 15).45 Compared with the 
aldehyde inhibitors, the representative compound 12 (SNJ-1757) was more stable to 
nucleophilic attack and has a better corneal permeability.   
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Figure 15: Synthesis of a prodrug cyclic hemiacetal.
Recently Tripathy et al. incorporated d-proline at the P2 position of inhibitors to obtain 
potent calpain inhibitor 13.46 The calpain inhibitory potency should be dependent of the 
size of P2 side chain. Compounds with a five-membered ring at the P2 -position are more 
potent inhibitor and show 150-fold selectivity for calpain I over cathepsin B.  
To improve the selectivity for -calpain, a series of urea-based peptidomimetic calpain 
inhibitors have been developed by replacement of P2 chiral carbon with nitrogen (Figure 
16). SAR shows that a benzyl group was preferred as the R1 substituent, the iso-butyl 
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group was the preferred R2 substituent and PhCH2O(CH2) was introduced as R3
substituent.47
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Figure 16 
  
Peptide-biphenyl hybrids have been evaluated and shown to be potent and selective 
calpain inhibitors.48 Unlike calpain inhibitors with electrophilic functionality, the 
aromatic groups in this species such as 14 interact with calcium binding sites rather than 
react directly with thiol group at the active site of calpain to hamper the activation of 
calpain. These compounds have been assayed and the IC50 values are in nanomolar scale. 
This strategy has increased the selectivity for calpain I over cathepsin B.  
Ketoamide 15 was the most potent compound [IC50 (9 nM)] and functions as a reversible 
calpain inhibitor with a 300-fold selectivity for calpain over cathepsin B. The 
characteristic of this compound has been achieved by the substitution of the P2 amino 
acid by peperidine carboxamides. P2 and P3 region can also be modified leading to a 
potent calpain inihibitor 16 which has a 150-fold selectivity for calpain I and vs. 
cathepsin B and reveals activity in cell culture.49
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1.7: Molecular modeling and structure activity relationships 
For our studies, the choice of a target compound for synthesis is a result of extensive 
molecular modelling to select molecules that well bind effectively in the active site of 
calpain. The X-ray structures of mini - and m-calpain mutant constructs (Figure 17) 
were used as a basis for molecular modeling. Examination of the structures reveals that 
the active site mini m-calpain calpain mutant construct is blocked by Trp106. It is 
proposed that this obstruction was caused by instability of an α-helix adjacent to the 
active site. Therefore molecular modeling was performed using a mini µ-calpain 
construct which was prepared as follows: addition of hydrogens, conversion of the serine 
in the active site to a cysteine, relaxation or minimisation of the structure, and mapping 
the active site. Further improvements of this model were achieved through deprotonation 
of cystein, and protonation of histidine. Enzyme inhibition assays were performed by 
using m-calpain, isolated from sheep lung by Matthew Muir at Lincoln University.  
         mini m-calpain                       mini -calpain 
Figure 17: Mini-m and mini- calpain models. 
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Computational modeling entails the development in the computer of thousands of 
molecular poses for a given inhibitor. Ten or so lowest energy poses are selected for 
docking with the rigid model of calpain. There are several parameters obtained from the 
docking protocol. Glide scores reflect the binding energy especially the hydrogen bonds 
between ligands and the enzyme. It is not correlated with the IC50 value but good binders 
tend to have a Glide Score of less than -6; A potent inhibitor must have a warhead with 
appropriate position for nucelophilic attack by Cys115, in other words, the distance of 
warhead to Cys115 should be less than 5Å. Visual and mathematical analysis of the 
molecule bound into the active site reveals whether or not it binds in a -strand 
conformation. The docking results of the first generation calpain inhibitors (Figure 7) is 
given in Table 2, and shows some correlation with assay results.  
Inhibitor Glide score H-bonding Extra H- 
bonding 
Warhead 
distance 
IC50
(nM) 
SJA6017 -6.6 A,B,C 0 3.94 80 
0066-JN -5.4 A,B,C 0 3.86 60 
0003-RP -6.2 A,B,C 1 3.78 80 
0002-SM -6.9 A,B,C 0 3.78 40 
0078-MJ -5.7 A,B,C 0 4.12 45 
0087-MJ -5.6 A,B,C 0 3.84 90 
Table 2: Results of the first generation cataract inhibitors generated by Blair Stuart. 
Rigid docking of some flexible ligands can give rise to anomalous results. The 
anticipated -strand conformation, warhead distance, and glide score are not well 
correlated with the experimentally determined binding affinities. This can be explained 
by Koshland’s theory of induced fit; that is, the substrate enters the active site and forces 
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it to take up the ideal shape to accommodate it. On the other hand, as the enzyme changes 
the shape to maximize the bonding interactions, it also alters the conformation of ligands. 
Induced fit docking can provide more accurate results but it is a much slower and more 
expensive docking protocol compared to the rigid docking.  
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Chapter 2: Results and discussion 
2.1: Synthesis 
The Val-Leu dipeptidyl aldehydes 33a-e, 33g, 33i and 35 have been synthesized. These 
target molecules were chosen as a result of molecular modeling studies (see section: 2.3). 
They share common characteristics in that modeling studies suggests that the bioactive 
-strand conformation is dominant in the conformational ensemble, that they will have 
suitable binding affinity to the enzyme and an appropriate warhead distance from the 
active site cysteine sulphur of the active site of calpain.  
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Figure 18: Retrosynthetic analysis of the Val-Leu dipeptidyl aldehydes (Series 33). 
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The discussion covers first the preparation of the carboxylic acids 17, 18, and 19 that 
were not commercially available and which form the left hand side (LHS) address region 
for some of the compounds we planned to study (see 2.1.1). This is followed by the 
preparation of the Val-Leu dipeptide core 29, and the Val-Leu dipeptidyl alcohols (31a-g 
and 31i). Finally we discuss the last step in the synthesis of the Val-Leu dipeptidyl 
aldehydes 33a-e, 33g, 33i and 35 (Figure 18).  
2.1.1: Synthesis of LHS starting materials 
Specifically the series of Val-Leu dipeptidyl aldehydes 33a-l, have been made to 
investigate the effect of left hand side address region on the inhibition of the cysteine 
protease, m-calpain. The left hand side groups are all derived from carboxylic acids that 
are deemed capable of forming appropriate hydrogen bonding interactions with the S3
pocket of m-calpain. In addition to nicotinic acid, pyridylacetic acid, and furan carboxylic 
acid which are commercially available, carboxylic acids 17, 18, and 19 containing 
pyridine, benzene and pyrrole groups were prepared. 
Modelling studies show that an aromatic group at left hand side is likely to bind to the S3
subsites of the enzyme. It is expected that the carbonyl groups of the pyridine carboxylic 
acid 17 and 2-pyrrole carboxylic acid 19 will contribute to H-bonding and facilitate an 
extended -strand conformation of the inhibitor upon binding to m-calpain. The pyrrole 
19 and amine 18 similarly have the capacity of forming the H-bonds in the S3 pocket 
(Figure 19).  
N
OH
O
MeO
O
BocHN
OH
O
N
H O
OH
H
O
17 18 19
Figure 19: Structure of synthesized left hand side starting materials. 
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The carboxylic acid 17 was prepared (Scheme 2) from commercially available pyridine-2, 
6-dicarboxylic acid 20 which was converted to the dimethyl ester 21 with methanol in the 
presence of thionyl chloride. A 6-H singlet in the 1H NMR spectrum at 3.9 ppm indicates 
the formation of the diester. Selective monohydrolysis using the method developed by 
Schmuck50 gave 2,6-pyridinedicarboxylic acid, mono methyl ester 17 as the sole product 
(98%) again confirmed by integration of the methyl ester peak in the 1H NMR. 
N
HO
O
OH
O
N
MeO
O
OMe
O
MeOH
  KOH
  MeOH
SOCl2
N
MeO
O
OH
O
20 21 17
  
Scheme 2: Synthesis of LHS 17.
In an attempt to synthesize 4-(N-tert-Butoxycarbonyl) aminobenzoic acid 18, BOC 
protection of 4-amino-benzoic acid methyl ester 22 was attempted (Scheme 3). The 
aminoester 22 in dioxane was stirred at room temperature for 18 hrs with sodium 
hydroxide (4 equiv) predissolved in distilled water and di-tert-butyl dicarbonate (4 equiv) 
added. This procedure failed and resulted only in the isolation of starting material. An 
alternative protection method was attempted where ester 22 was reacted with 
tert-butoxycarbonyl in the presence of DMAP as catalyst. This reaction yielded a mixture 
of mono 23 and di 23a protected products. Purification of these compounds was not 
attempted as literature precedence51 indicated a second BOC group on an amine is base 
labile and the next step in the synthesis of 18 was a base mediated ester hydrolysis. A 
mixture of 23 and 23a was therefore hydrolyzed with an excess of base (4 equivalents) to 
give corresponding mono BOC protected aminobenzoic acid 18 in excellent yield (89%).  
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Dioxane
NaOH/H2O
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Boc
Boc
23a
(Boc)2O
DMAP
THF
THF/H2O
(Boc)2O
NaOH
Scheme 3: Synthesis of the LHS 18.
BOC protection of aminobenzoic methyl ester 22 is catalyzed by DMAP via acylation of 
the pyridine ring to give a highly reactive pyridinium species which undergoes 
nucleophilic attack by amine to give 23 at the same time regenerating the catalyst 
(Scheme 4).52 The presence of the BOC group was confirmed by the appearance of a 
large singlet at 1.45 ppm in 1H NMR spectra.  
N
N
O O
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N
N
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H2N
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O OMe
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H
+
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N
22 23
Scheme 4: BOC protection catalyzed by DMAP. 
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The synthesis of 4 –formyl-pyrrole-2-carboxylic acid 19 was achieved via hydrolysis of 
the corresponding ester 25 in an excellent yield (85%) (Scheme 5). The starting ester 25 
was synthesized using a formylation reaction of 2-pyrrole ethyl ester 24 followed by 
chromatographic separation of the 4- and 5-formyl isomeric mixture.
N
H
OEt
O
N
H
OEt
O
H
O
N
H
OH
O
H
O
KOH
H2O
POCl3
DMF
DCE
24 25 19
Scheme 5: Synthesis of LHS 19. 
2.1.2: Synthesis of Val-Leu dipeptide core 
Inhibitors can be schematically divided into LHS, dipeptide core and warhead (Figure 
20). Various aromatic groups have been designed and substituted at the left hand side of 
inhibitors for enzyme recognization. Aldehyde has been used as a warhead since this 
electrophilic carbonyl group can form reversible covalent adduct with the active cysteine 
site of calpain. The peptide core consists of a Val-Leu dipetide and is believed to exhibit 
favourable hydrophobic interaction in the S1 and S2 pockets of m-calpain.  
LHS 
aromatic
Core: dipeptide
Aldehyde
warhead
S
H
N
O O
N
H
O
H
O
F
Figure 20: Val-Leu dipeptidyl aldehyde. 
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The Val-Leu dipeptide core 29 was synthesized by coupling of commercially available 
Boc-Valine 26 and L-Leucinol 27 to give N-Boc-Val-Leu-OH 28 (54%) which after 
hydrolysis gives the hydrochloride salt 29 (Scheme 6). 
BocHN
OH
O
H2N
OH
BocHN
N
H
O
OH
H3N
N
H
O
OH
DMF, DIPEA
HATU
4M HCl
dioxane
26 27 28
29
Cl
  
Scheme 6: Synthesis of the dipeptide core hydrochloride salt 29.
The peptide coupling reaction to give dipeptides 28 was carried out under mild conditions 
using HATU as the coupling regent. This reaction proved to be robust and multigram 
quantities (>10g) of 28 were prepared.  
Acidolysis of BOC-dipeptide 28 by hydrogen chloride is employed to remove 
tert-buoxycarbonyl group. The cleavage is initiated by protonation of the carbonyl 
followed by electron shift to give a carbenium ion. The carbenium ion is fragmented into 
tert-butyl cation followed by reaction with a nucleophile chloride counter-ion to give 
tert-butyl chloride (SN2 mechanism) and acid carbonate. The acid carbonate has a 
hemiacetal structure which is easy to decompose to liberate carbon dioxide (Scheme 7).53
Deprotection of 28 to give amine salt 29 is usually carried out at 60oC since the 
                                                                                41
carbenium ion is relatively stable and usually requires heat for fragmentation. The 
removal of the BOC group can be seen by the disappearance of a large singlet at 1.3 ppm 
in 1H NMR spectrum.  
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Scheme 7: Deprotection of BOC by acidolysis. 
2.1.3: Synthesis of Dipeptidyl Alcohols 
The Val-Leu dipeptide alcohols 31a, 31b, 31c, 31d, 31e, 31f, 31g and 31i were prepared 
by coupling the hydrochloride salt 29 with corresponding carboxylic acids 30 using 
HATU or EDC as coupling reagents (Scheme 8).   
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Scheme 8: Synthesis of amino alcohols 31a-31l. 
An important strategy for the synthesis of these dipeptidyl alcohols 31a-l is the choice of 
coupling regent as this can affect yield and stereochemistry. HATU is an efficient 
coupling regent for coupling sterically hindered amino acids.54 The mechanism of HATU 
coupling is shown in Figure 21.  
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Figure 21: General mechanism of HATU coupling reactions. 
HATU was employed as the peptide coupling regent for the synthesis of Val-Leu 
dipeptidyl alcohols 31b and 31c. Compound 31b was prepared by coupling pyridine 
carboxylic acid and dipeptide core 29 (83% yield). 4-tert-Butoxycarbonylaminobenzoic 
acid was coupled with 29 to give 31c (65%) (Scheme 9).  
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Scheme 9: Synthesis of amino alcohols 31 b and 31c. 
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HATU is a highly reactive coupling reagent and in some cases can give rise to undesired 
side reaction (Scheme 10). Commercially available nicotinic acid reacted with 29 in the 
presence of HATU as a coupling regent and gave the desired amino alcohol 31d, 
however the 13C NMR of the product showed that esterification had occurred to form a 
mixture of compounds 31d and 32. The spectrum shows four carbon signals 
corresponding to the two α-carbons of the two products (60.18, 60.22, 64.27 and 66.64 
ppm) (Figure 22). 
H3N
N
H
O
OH
HATU
DIPEA, DMF
H
N
O
N
H
O
OH
N
OH
O
N
31d29
H
N
O
N
H
O
O
N
32
Cl
O
N
Scheme 10: HATU coupling of nicotinic acid to dipeptide 29. 
Figure 22: Section of the 13C NMR spectrum of the HATU mediated coupling of 
nicotinic acid to dipeptide 29. 
Due to the esterification side reaction using HATU chemistry, a coupling reaction of 
nicotinic acid with dipeptide 29 was performed using EDC/HOAt and with EDC/HOBt in 
an attempt to make 31d in the absence of ester (Scheme 11).  
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Scheme 11: Synthesis of amino alcohol 31d using a variety of coupling conditions 
An EDC/HOBt coupling of nicotinic acid to dipeptide 29 again resulted in some 
esterication. However, an EDC/HOAt mediate coupling reaction where the stoichoimetry 
of the reagents had been changed from 1:1 equivalents (dipeptide:nicotinic acid) to 1.5:1 
resulted only in the formation of 31d. The 13C NMR spectrum of the EDC/HOAt reaction 
clearly shows that no esterification had occurred and only 31d was formed. Only two 
α-carbon signals can be observed (60.16 and 64.25 ppm) (Figure 23).  
Figure 23: Section of the 13C NMR spectrum of the EDC/HOAt mediated coupling of 
nicotinic acid to dipeptide 29. 
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Based on the above results, EDC/HOAT mediated coupling was used for the synthesis of 
31e-i. Compound 31e was synthesized by coupling 5-formyl-furan-2-carboxylic acid and 
dipeptide core 29 (31%). Compound 31f was obtained by condensation of 
2,4,6-trimethoxy-benzoic acid and compound 29 (76% yield). 4-Formyl-1H-pyrrole-2- 
carboxylic acid and 1H-indole-2-carboxylic acid were coupled with core 29 to give 
compounds 31g and 31i (36% and 70% respectively) (Table 3). A pure sample of 
compound 31h was not obtained as the product from peptide coupling was water soluble 
resulting in difficult extraction, separation and purification from the by-products of 
reaction. Examination of the 13H NMR of compounds 31e-g and 31i showed no evidence 
of esterification. 
Compound 31a was prepared in 43% yield by reaction of 2-pyridylacetic acid and 
dipeptide core 29 effected by EDC/HOAT. The yield was improved to 61% by using the 
phosphonium reagent PyBroP as coupling reagent.
The yields of the Val-Leu dipeptidyl alcohols 31a-l are summarized in Table 3.  
R
H
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31: dipeptidyl alcohols
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No. R Structure Yield 
31a
N H
N
O
N
H
O
OHN 61% 
31b N
O
O
H
N
O
N
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O
O
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O
H
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O
N
H
O
OH
H
NO
O
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N H
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N
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H
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OO
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OO
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H H
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N
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H
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31i 
N
H
H
N
O
N
H
O
OH
N
H
70% 
31j HN
N
H
N
O
N
H
O
OH
HN
N 0% 
31k 
N
N
H
H
N
O
N
H
O
OH
N
N
H
0% 
31l N
H
O
H
N
O
N
H
O
OH
N
H
O
Trace amounts 
Table 3: Yields for the synthesis of amino alcohols 31a-l. 
Conventional coupling procedures are not suitable in the synthesis of compounds 31j and 
31k since imidazole-carboxylic acid has poor solubility in DMF. A potential alternative 
synthesis of 31j and 31k is to utilize microwave irradiation with HOBT and 
di-isopropylcarbodiimide (DIC) as coupling reagents. Microwave irradiation has been 
employed in several cases to direct condensation of amines and carboxylic acids.55
Peptide coupling reactions under microwave irradiation can reduce the reaction time, 
reduce side reactions, and increase the yield of product and sometimes proceed even 
without an activation catalyst.56 However, due to time constraints microwave chemistry 
was not attempted. 
                                                                                49
The synthesis of compound 31l was attempted using HATU and EDC/HOAT regents 
under a mild condition, however, no coupled product was observed. Coupling reactions 
involving pyroglutamic acid are notoriously difficult. A alternative method synthesize 
compound 31l was made using the method developed by David et al 57 at 0 °C using 
HATU but only trace amounts of the product were formed. 1H NMR and TLC analysis 
shows that the isolated material was mainly unreactived starting material. An alternative 
method for coupling on a small scale in DMF using HBTU is known; however, as large 
quantities of 31l are required this method was not attempted.58  
2.1.4: Synthesis of Val-Leu dipeptidyl aldehydes 
The dipeptidyl alcohols 31a-l were oxidized with activated dimethyl sulfoxide (DMSO) 
to the corresponding dipeptidyl aldehydes 33a-g, and 33i. These aldehydes were assayed 
against m-calpain to measure their ability to act as inhibitors (Scheme 12).  
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DCM, DMSO
Scheme 12: General procedure for the oxidation of amino alcohols 31a-l 
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Dimethyl sulfoxide (DMSO) as an oxidizing reagent can be activated by several 
electrophlies such as dicyclohexylcarbodiimide (DCC),59 acetic anhydrid,60 phosphorous 
pentoxide,61trifluoroacetic anhydride,62oxalyl chloride,63 and complex SO3.Pyr.
64 The 
activated DMSO can react with a primary alcohol to form the corresponding aldehyde or 
ketone.   
Swern oxidation with oxalyl chloride as activator was attempted for the oxidation of 31a, 
but the yield was low. This is probably due to the sensitivity of the method to moisture 
and temperature. The reaction is carried out at minus 60°C because that oxalyl chloride is 
a strong activator and the resulting highly reactive DMSO complex can decompose to the 
methylene sulfonium salt. Pummerer rearrangement occurs if temperature is above -60oC 
(Figure 24).  
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Figure 24: Swern oxidation pathway and Pummerer rearrangement. 
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Compared with oxalyl chloride, SO3/pyridine is a mild activator and can activate DMSO 
even at room temperature. The resulting activated DMSO is less reactive and methylene 
sulfonium salt is less easily formed. Oxidation of 31a with SO3/pyridine complex was 
carried out to give 33a in 45% yield indicating it to be more effective than Swern 
oxidation (Scheme 13). Therefore this method is used for amino alcohols 31a-f, 31g and 
31i. The best yield was obtained using a mixture of DMSO/DCM (2:1) as solvent. The 
reaction should be cooled on ice bath for 2 hours. However, all attempts to oxidize 31f
under these conditions failed. No explanation for this apparent lack of activity can be 
proposed.  
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N
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N
O
N
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O
N
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O
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SO3Pyr, DMSO
 DCM, DIPEA
DMSO, (COCl)2
DIPEA, DCM
- 60 oC
45%31a 33a
33a
N
H
N
O
N
H
O
OH
31a
Scheme 13: Oxidation of 31a using two conditions. 
As shown in Figure 25, DMSO reacts with SO3.Pyr to form a sulfonium species which 
contains a good-leaving group linked to the positive sulfur atom. The leaving group was 
then displaced with alcohol to yield an alkoxydimethylsulfonium salt followed by 
deprotonation by DIPEA to form the sulfur ylide. Intramolecular eliminiation leads to the 
formation of carbonyl compound and dimethyl sulfide.  
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Figure 25:  DMSO oxidation with sulphur trioxide pyridine as an activating reagent. 
The yield of the dipeptidyl aldehydes 33a-g and 33i from sulfur trioxide pyridine 
oxidation are presented in Table 4.  
R
H
N
O
N
H
O
O
33: dipeptidyl aldehydes
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No. R Structure Yield 
33a
N H
N
O
N
H
O
ON 45% 
33b N
O
O
H
N
O
N
H
O
O
N
O
O

49% 

33c 
H
NO
O
H
N
O
N
H
O
O
H
NO
O

57% 
33d 
N
H
N
O
N
H
O
O
N
61% 
33e O
H
O
H
N
O
N
H
O
O
O
H
O 88% 
33f 
OO
O
H
N
O
N
H
O
O
OO
O
0% 
33g
N
H
O
H
H
N
O
N
H
O
O
N
H
O
H
86% 
33i 
N
H
H
N
O
N
H
O
O
N
H
81% 
Table 4: Oxidation yields results. 
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Chemical modification of compounds 33b and 33c was attempted with the aim of 
forming two further calpain inhibitors 34 and 35. Base mediated hydrolysis of the ester 
33b was attempted but failed to yield the corresponding carboxylic acid 34 (Scheme 14).  
N
O
O
H
N
O
N
H
O
O
N
HO
O
H
N
O
N
H
O
O
THF/H2O
NaOH33b 34
X
Scheme 14: Hydrolysis of methyl ester 33b.
Hydrochloride salt 35 was synthesized via BOC deprotection of 33c using 4M HCl in 
dioxane to give an inhibitor expected to participate in hydrogen bonding within the S3
pocket (Scheme 15). The loss of the BOC group in compound 33c was shown by the 
disappearance of singlet at 1.3ppm in 1H NMR. 
BocHN
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98%
Scheme 15: BOC deprotection of 33c.
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2.2: Assay and molecular modeling results 
The aldehydes 33a-e, 33g, 33i and 35 were assayed against m-calpain using a 
fluorescence-based assay65 to determine in vitro potency. The inhibition constant (IC50) 
were determined (see appendix). Four compounds 33a, 33d, 33e and 33g display active 
inhibition and function as potent calpain inhibitors (Figure 26).   
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Figure 26: Structures of calpain inhibitors with nanomolar IC50 value.
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The most potent calpain inhibitor synthesized is 33a and its IC50 value is 28 nM. Based 
on the modeling results (Table 5), three hydrogen bonds (A, B, C) are formed between 
the backbone of ligand 33a and Gly208 and Gly271 of calpain resulting in a bioactive 
-strand conformation.66
Compounds Glide score H-bonding Extra H- 
bonding 
Warhead 
distance 
IC50
33a -5.9 A,B,C 1 4.39 28 nM 
33b -5.1 A,B,C 1 4.07 3.56 M
33c -5.1 B,C 1 3.89 5.80 M
33d -4.8 A,B,C 0 3.93 86 nM 
33e -5.23 A,B,C 0 4.09 99 nM 
33g -5.2 A,B,C 1 3.77 103 nM 
33i -6.0 - 3 3.39 3.43 M 
35  27.6 M 
Table 5: Molecular docking results. 
The inhibitor 33d is potent. Its IC50 value is 86 nM. The activity of Val-Leu dipeptidyl 
aldehydes 33a, 33d is in accord with the docking studies that indicate valine is preferable 
at P2 for binding in the S2 pocket residues with Ala273, Ser251 and other amino acids while 
leucine interacts favorably with Leu260 and Glu261 residues in S1 pocket. 
Pyridin-2-yl-acetaldehyde and pyridine-3-carbaldehyde at the P3 site are favorable for 
binding in the S3 subsites.  
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(S)-N-((S)-1-Formyl-3-methyl-butyl)-3-methyl-2-(2-pyridin-2-yl-acetylamino)-butyrami
de 33a is a more potent inhibitor than 33d. This may be a result of it having one more 
hydrogen bond between ligand 33a and Lys347 in the S3 pocket (Figure 27).  
Figure 27: Molecular modeling of 33a (left) and 33d (right) in the S3 binding site of 
m-calpain.  
A comparison of 33e (99nM) and 33g (103nM) shows that the 5-formylfuran and 
4-formylpyrrole function as both N-terminal capping substituents and are well 
accommodated in the S3 pocket of m-calpain. This is consistent with their similar IC50
values. Molecular modeling shows similar binding in the active site for the both 
compounds. Furan 33e binds in a standard β-stand conformation with the three defining 
hydrogen bonds A, B, C but no additional hydrogen bonds; whereas, 33g binds in a 
standard β-strand conformation but contains an additional hydrogen bond to Lys347 in the 
S3 pocket (Figure 28). Even though 33g contains an additional hydrogen bond the 
increasing activity of 33g compared to 33e may be attributed to less steric hindrance in 
the S3 pocket for 33g.  
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Figure 28: Molecular modeling of furan 33e (red) and pyrrole 33g (light blue) in the S3
binding site of -calpain.  
Removal of the BOC protecting group of 33c (5.8M) to give hydrochloride salt 35
(27.6M) results in a dramatic decrease in potency against m-calpain. The poor inhibition 
of 35 indicates that the charge group is not accommodated well in the S3 pocket. Further 
comparison of the protected aniline 33c (5.8M) and 33b (3.65M) reveals that Glide 
scores and warhead distances of these two compounds are similar; however, 33b exhibits 
one more hydrogen bond than 33c and even more importantly 33b binds in an extended 
-strand conformation (defined by three hydrogen bonds: A, B, C) resulting in more 
potent inhibition of m-calpain than 33c. 
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Compound 33i (3.43M) has a good glide score (-6.0) indicating tight binding with 
m-calpain. The warhead is in close proximity to the active site (3.39Å); however, no 
hydrogen bonding occurs between the backbone of ligand 33i and Gly208 and Gly271 of 
calpain. As shown in Figure 29, pyrrole NH and amide at P2 position form two hydrogen 
bonds with Ser206. The warhead carbonyl also exhibits a hydrogen bond with His272. 
Despite these three hydrogen bonds, the modeling shows that the inhibitor is not in a 
-strand conformation; and compound 33i has only moderate activity.  
Figure 29: Molecular modeling of 33i in the S3 binding site of m-calpain. 
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2.3: Conclusion 
The potent inhibitors discussed in this thesis were designed using SJA6017 as a reference. 
The dipeptide core of this compound has been used as a scaffold for the attachment of 
functional group with the ability to participate in hydrogen bonding. IC50 values of the 
inhibitors 33a-e, 33g, 33i and 35 were determined. Four compounds (33a, 33d, 33e, and 
33g) gave potent nanomolar inhibition with the best compound 33a (28nM) having an 
IC50 lower than SJA6017 (80nM). Compounds 33a and 33d contain a pyridine ring at the 
P3 site and this can improve the corneal permeability in comparison with SJA6017 known 
to exhibits poor corneal permeability. Compound 33g has a pyrrole group in place of the 
N-4-fluorophenylsulfonyl of SJA6017 at the P3 position of SJA6017 and displays an 
active inhibition (103 nM). Furan based peptide 33e has an IC50 99 nM. Molecular 
modeling shows compounds 33c (5.8 M) and 33i (3.43 M) fail to bind in a - strand 
conformation and these compounds exhibit only moderate activity. 
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Chapter 3: Experimental  
3.1: General experimental methods and procedure 
Analytical thin layer chromatography (TLC) was performed on plastic-backed Merck 
Nagel SIL G/UV254 PLATES. Visualisation was achieved by ultraviolet light and 
KMnO4 solution or PMA. Flash chromatography was performed on 230-400 mesh Merck 
Silica gel 60 using the Buchi sepacore flash automated chromatography system. All 
eluting solvents were distilled beforehand. Proton NMR spectrometry were obtained on a 
Varian Inova spectrometer operating at 300 MHz. Carbon NMR spectra were obtained on 
a Varian Inova spectrometer operating at 75 MHz with a delay of (D1) of 1s. Spectra 
were obtained at 23°C. Chemical shifts are reported in parts per million (ppm) on the 
scale. Mass spectra were performed on a Kratos MS80 RFA mass spectrometer operating 
at 4000V (accelerating potential) and 70 eV (ionization energy) using a Kratos MS80 
RFA spectrometer with a 250°C source. The melting points were obtained on an 
Electrothermal apparatus and are uncalibrated.  
General procedure A1: O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium  
hexafluorophosphate (HATU) mediated peptide coupling 
The acid (1 equiv), ammonium salt 29 (1.1 equiv) and HATU (1.1 equiv) were dissolved 
in dry DMF. DIPEA was added (4 equiv) and the reaction mixture stirred at room 
temperature overnight. The solution was diluted with EtOAc (5:1), washed with water 
(2x) and brine, dried over MgSO4, concentrated in vacuo and purified by column 
chromatography. See individual experiments for specific details. 
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General procedure A2: HATU mediated peptide coupling  
The acid (1 equiv), ammonium salt 29 (1.5 equiv) and HATU (1.2 equiv) were dissolved 
in dry DMF. DIPEA was added (2.4 equiv) and the reaction mixture stirred at room 
temperature overnight. The solution was diluted with EtOAc (5:1), washed sequentially 
with HCl (1M), saturated NaHCO3 and brine and dried over MgSO4, filtered and 
concentrated in-vacuo. See individual experiments for specific details.
General procedure A3: 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide  
hydrochloride (EDC) mediated peptide coupling
The acid (1 equiv), ammonium salt 29 (1.5 equiv), EDC (1.2 equiv), and HOAT (1.2 
equiv) and were dissolved in anhydrous DMF. DIPEA was added (2.4 equiv) immediately 
and the reaction mixture stirred at room temperature for 18hr. The solution was diluted 
with EtOAc (5:1), washed with water (2x) and brine, and dried over MgSO4, 
concentrated in vacuo and purified by column chromatography. See individual 
experiments for specific details. 
General procedure A4: PyBrop mediated peptide coupling 
The acid (1 equiv), ammonium salt 29 (1.5 equiv) and PyBrop (1.2 equiv) were dissolved 
in dry DMF (1ml/60 mmol). DIPEA was added (2.4 equiv) and the reaction mixture 
stirred at room temperature overnight. The solution was diluted with EtOAc (5:1), 
washed sequentially with HCl (1M), saturated NaHCO3 and brine before being dried over 
MgSO4, filtered and concentrated in-vacuo. See individual experiments for specific 
details.  
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General procedure B: Sulfur trioxide/pyridine complex oxidation  
A solution of the alcohol in a 2:1 mixture of DMSO and DCM (0.10M) was cooled in ice.  
To this DIPEA (4 equiv) and a solution of SO3.Pyr complex pre-dissolved in DMSO 
(1ml/60mol) was added dropwise. The mixture was stirred in ice for 2 hr or until TLC 
indicated complete consumption of the starting alcohol. The reaction mixture was diluted 
with ethyl acetate (10:1), washed with HCl (1M, 2x), saturated NaHCO3 (2x) and brine 
before being dried over MgSO4, filtered and concentrated in vacuo. See individual 
experiments for specific details.
General procedure C1:  Ester hydrolysis with base 
To a solution of ester in THF/H2O (3:1, 1ml/10mg) was added NaOH (2.5 equiv) and the 
solution was heated to 65oC with stirring overnight. The mixture was concentrated in 
vacuo and the residue was partitioned between EtOAc (100ml) and water (100ml). The 
aqueous layer was acidified to pH 2 with 1M HCl and extracted with EtOAc (2x). The 
combined EtOAc layers were washed with water, brine, and dried over MgSO4 and 
concentrated in vacuo. See individual experiments for specific details. 
General procedure C2:  Ester hydrolysis with base 
To a solution of the ester in methanol was added NaOH (4 equiv) pre-dissolved in H2O. 
The solution was heated to 65oC with stirring overnight. The aqueous layer was acidified 
to pH 2 with 1M HCl and the product extracted with EtOAc (2x). The combined EtOAc 
layers were washed with water, brine, and dried over MgSO4. The solvent was removed 
in vacuo. See individual experiments for specific details.
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General procedure D: Esterification with SOCl2 and methanol: 
The carboxylic acid was suspended in methanol and cooled on ice bath. Thionyl chloride 
(1:10) was added dropwise and the solution was stirred at 0oC for 3 hours before being 
concentrated in-vacuo. See individual experiments for specific details. 
General procedure E1: N-BOC protection of an amino acid 
The amino acid was dissolved in 1,4-dioxane. To this were added NaOH (4equiv) 
pre-dissolved in distilled water (dioxane-water 1:1), followed by di-tert-butyl dicarbonate 
(1.2 equiv). The mixture was stirred at room temperature overnight before being 
concentrated in vacuo. The residue was partitioned between ethyl acetate and 1M HCl. 
The aqueous phase was extracted twice with ethyl acetate and the combined organic 
extracts were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. 
See individual experiments for specific details. 
General procedure E2: DMAP mediated N-BOC protection  
Amine was dissolved in THF. Di-tert-butyl dicarbonate (5 equiv) and DMAP (1.1 equiv) 
were added dropwise. The mixture was stirred stirred overnight and the product isolated 
by concentration in vacuum. See individual experiment for specific details.  
General procedure F: BOC deprotection with 4M HCl in dioxane 
The N-BOC protected compound was dissolved in 4M HCl in dioxane (100mg/ml) and 
the solution stirred at room temperature overnight. The solvent was removed in vacuo. 
See individual experiment for specific details. 
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3.2: Experimental 
6-(Methoxycarbonyl) pyridine-2-carboxylic acid (17)
N
OH
O
MeO
O
A solution of dimethyl pyridine-2, 6-dicarboxylate (11.6 g, 59.4 mmol) in methanol (300 
ml) was cooled to 0oC. Potassium hydroxide pellets (3.39g, 60.29 mmol) were added and 
the reaction mixture was stirred at 0oC for 2hr and then at room temperature for 24hr. The 
solvent was removed under reduced pressure, and the residue was suspended in ethyl 
acetate (150 ml). The white potassium salt was collected by filtration and dissolved in 
water (100 ml). The solution was acidified to pH 3 with concentrated hydrochloric acid 
and extracted with chloroform (3x100 ml) and dried over MgSO4. The chloroform was 
removed in vacuo to provide the 17 (2.90 g, 53%) as a white solid. m.p 146oC.67 H 
(CDCl3) 2.15 (1H, s, NH), 4.0 (3H, s, COOCH3), 8.19 (1H, s, ArH), 8.32 (2H, d, 2ArH). 
13C NMR (75 MHz in DMSO) 52.6 (CO2CH3), 127.6 (CCHCH), 127.8 (CCHCH), 139.0 
(CCHCH) , 147.6 (NCCH), 148.9 (NCCH), 164.8 (CO2CH3), 165.6 (CO2H); m/z (ES) 
[M+(H)]+ 182 (50%); [M+Na]
 + 204 (25%). 
4-(N-tert-Butoxycarbonyl) aminobenzoic acid (18) 
BocHN
OH
O
68
The ester 23 (920mg, 0.836mmol) was dissolved in THF (20 ml) and to this was added 
NaOH (4 equiv) pre-dissolved in water (20 ml). The reaction solution was stirred at 60oC 
overnight and concentrated to remove THF. The residue was washed with ethyl acetate 
(50 ml) and was acidified to pH 2 with 1M HCl. The aqueous layer was re-extracted with 
ethyl acetate (2 x 50 ml). The combined organic phase was washed with NaHCO3, brine, 
and dried over MgSO4. The solution was concentrated under reduced pressure to give the 
product 18 as a white solid (768mg, 88.5%). mp 191-192 °C; H (CDCl3) 1.50-1.56 (9H, 
m, (CH3)3), 6.67 (s, NH), 7.41 (2H, d, 2ArH), 7.95 (2H, d, 2ArH).   
4-Formyl-1H-pyrrole-2-carboxylic acid (19) 
N
H
O
H
OH
O
The methyl ester 25 (2.17g, 13mmol) was hydrolysed using general procedure C2 to 
afford 19 as yellow solid (1.53g, 85%). mp 234-236oC. 1H NMR (300 MHz in (CD3)2SO) 
7.07 (1H, d, ArH), 7.77 (1H, d, ArH), 9.74 (1H, s, CHO), 12.53 (1H, s, NH Pyrrole), 
12.85 (1H, s, CO2H); 
13C NMR (75 MHz in DMSO). 112.5 (CHCNH), 125.6 (CHNH), 
126.5 (CHCCHO), 130.8 (CHCCO2H), 161.5 (CCO2H), 185.8 (CHO),
68 LRMS (ES) 
140.0 (MH+). C6H5NO3 requires 140.0. 
Pyridine-2, 6-dicarboxylic acid dimethyl ester (21) 
N
OMe
O
MeO
O
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Pyridine-2, 6-dicarboxylic acid (10g, 59.8mmol) was treated using general procedure D 
to provide dimethyl pyridine-2, 6-dicarboxylate as a white solid (11.72g, 100%). H 
(CDCl3) 2.11 (1H, s, NH), 4.0 (6H, s, 2 COOCH3), 7.98 (1H, s, ArH), 8.27 (2H, d, 
2ArH). m.p. 117 – 119oC; (Found: C, 55.45; H, 4.60; N, 7.18%. C9H9O4N requires C, 
55.43; H, 4.65: N, 7.18%).69 The crude product was used in the following step without 
further purification. 
4-tert-Butoxycarbonylamino-benzoic acid methyl ester (23) 
BocHN
OMe
O
4-Amino-benzoic acid methyl ester 22 (2g, 13.23mmol) was reacted with di-tert-butyl 
dicarbonate using general procedure E2. The crude product was purified with flash 
column chromatography over silica gel with ethyl acetate/ petroleum ether (gradient 1/3 
to 1/4) as eluent to give compound 23 as a white solid (2.4g, 72%). Rf = 0.30; H (CDCl3) 
1.38-1.42 (12H, d, (CH3)3), 3.91 (3H, s, COOCH3), 7.25 (2H, d, 2ArH), 8.05 (2H, d, 2 
ArH). m/z (ES) [M+(H)]+ 253 (60%); [M+Na]
 + 272 (25%).
[(S)-1-((S)-1-Hydroxymethyl-3-methyl-butylcarbamoyl)-2-methyl-propyl]- 
carbamic acid tert-butyl ester (28) 
BocHN
N
H
O
OH
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BOC Val-OH 26 (15.93g, 0.0734mol) was reacted with L-Leucinol 27 using the general 
procedure A2. The crude product was purified with flash column chromatography over 
silica gel using ethyl acetate - petroleum ether (1:1) as eluent to give 28 as a white solid 
(12.19g, 53%). Rf=0.4; H (CD3OD) 0.88-0.98 (12H, m, (CH3)4), 1.30-1.40 (9H, m, 
C(CH3)3), 1.30–1.50 (2H, m, CHCH2CH(CH3)2), 1.70 (1H, m, CHCH2CH(CH3)2), 1.98 
(1H, m, CHCH(CH3)2), 3.55 (2H, t, CH2OH), 3.80 (1H, d, CHCH(CH3)2), 4.0 (1H, m, 
CHCH2CH(CH3)2). 
13C NMR (75 MHz, CDCl3) 18.0 (CH3), 19.2 (CH3), 22.0 
(CH2CH(CH3)2), 23.0 (CH3), 24.7 (CH3), 28.2 (C(CH3)3), 30.4 (CH(CH3)2), 39.8 
(CH2CH(CH3)2), 49.9 (CHCH2OH), 60.5 (CHCH(CH3)2), 65.5 (CH2OH), 80.9 
(C(CH3)3), 156.1 (BocCO), 172.2 (CONH). HRMS (ES+) calcd. for C16H33N2O4 (M+H
+) 
317.2240 found 317.2249. 
(S)-2-Amino-N-((S)-1-hydroxymethyl-3-methyl-butyl)-3-methyl-butyramide (29) 
H3N
N
H
O
OH
Cl
BOC-Val-Leu-OH 28 (12.19g) was reacted using general procedure F to afford 29 as a 
white solid (10.2g, 100%). mp 82-86oC. This product was used without further 
purification. H (CD3OD) 0.90 (3H, d, CH3), 0.94 (3H, d, J 6.3, CH3), 1.03 (3H, d, J 6.8, 
CH3), 1.06 (3H, d, J 6.8, CH3), 1.30–1.40 (2H, m, CHCH2CH(CH3)2), 1.65 (1H, m, 
CHCH2CH(CH3)2), 2.2 (1H, m, CHCH(CH3)2), 3.5 (2H, t, CH2OH), 3.7 (1H, d, 
CHCH(CH3)2), 4.0 ( 1H, m, CHCH2CH(CH3)2). 
13C NMR (75 MHz in DMSO) 17.9 
(CH3), 18.2 (CH3), 21.9 (CH2CH(CH3)2), 23.3 (CH3), 23.9 (CH3), 29.7 (CH(CH3)2), 49.2 
(CHCH2OH), 57.3 (CHCH(CH3)2), 63.4 (CH2OH), 167.1 (CONH). (Found C, 48.67; H, 
71
9.81; N, 10.50% C11H25ClN2O2.H2O requires C, 48.79; H, 10.05; N, 10.34%). HRMS 
(ES+) calcd for C11H25N2O2 [M+H]
+ 217.1916 found 217.1924. 
(S)-N-((S)-1-Hydroxymethyl-3-methyl-butyl)-3-methyl-2-(2-pyridin-2-yl-acetylamio)
-butyramide (31a) 
H
N
N
H
O
OH
O
N
2-Pyridylacetic acid 30a (0.344 g, 1.978 mmol) was reacted with ammonium salt 29
using the general procedure A4. The crude product was purified with flash column 
chromatography over silica gel using MeOH-DCM (5%) as eluent to give 31a as a white 
solid (404mg, 61%). Rf=0.4; H (CD3OD) 0.83 (3H, d, CH3), 0.85 (3H, d, CH3), 0.86 
(6H, d, (CH3)2), 1.33 (2H, m, CHCH2CH(CH3)2), 1.61 (1H, m, CHCH2CH(CH3)2), 2.17 
(1H, m, CHCH(CH3)2), 3.43 (2H, t, CH2OH), 3.77 (1H, d, CHCH(CH3)2), 3.98 ( 1H, m, 
CHCH2CH(CH3)2), 4.18 ( 2H, d, CH2CO), 7.23 ( 1H, d, NH), 7.37 (1H, d, NH), 7.78 (2H, 
m, 2ArH), 8.23( 2H, s, 2ArH). 13C NMR (75 MHz, CD3OD) 17.1 (CH3), 18.4 (CH3), 
20.8 (CH3), 22.6 (CH3), 24.5 (CHCH2CH(CH3)2), 29.3 (CHCH(CH3)2), 30.3 
((CH(CH3)2), 39.7 (CHCH2CH(CH3)2), 47.8 (CHCH2OH), 48.6 (CHCH2CH(CH3)2), 
59.3 (CHCH(CH3)2), 64.2 (CH2OH), 122.2 (NCHCHCHCH), 124.1 (NCHCHCHCH), 
137.4 (NCHCHCHCH), 148.5 (NCHCH), 157.1 (CONH), 170.3 (CONH); m/z (ES) 
[M+(H)]+ 337 (45%); [M+Na]
 + 358 (25%). 
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6-[(S)-1-((S)-1-Hydroxymethyl-3-methyl-butylcarbamoyl)-2-methyl- 
propylcarbamoyl]-pyridine-2-carboxylic acid methyl ester (31b) 
N
O
O
H
N
O
N
H
O
OH
Pyridine carboxylic acid 17 (500 mg, 2.77 mmol), ammonium salt 29 (701.46 mg, 2.77 
mol), DIPEA (1.1 ml, 6.66 mmol), HOAT (453 mg, 3.33 mmol) and HATU (1.16 g, 3.05 
mmol) were dissolved in DMF. The solution turned yellow and was stirred overnight. The 
mixture was diluted with ethyl acetate, and the organic layer washed with aqueous HCl, 
(1M) saturated aqueous NaHCO3 and brine, and dried over MgSO4. The solvent was 
removed in vacuo. The crude product was purified by flash column chromatography over 
silica gel using ethyl acetate - petroleum ether (gradient 1:1 to 2:1) as eluent to give 31b
as a white solid (874 mg, 83.2%). Rf= 0.45; H (CD3OD) 0.90 (3H, d, CH3), 0.94 (3H, d, 
J 6.3, CH3), 1.03 (3H, d, J 6.8, CH3), 1.06 (3H, d, J 6.8, CH3), 1.35-1.45 (2H, m, 
CHCH2CH(CH3)2), 1.70 (1H, m, CHCH2CH(CH3)2), 2.17 (1H, m, CHCH(CH3)2), 3.51 
(2H, t, CH2OH), 3.77 (1H, d, CHCH(CH3)2), 4.02 (3H, m, COOCH3) 4.38 ( 1H, m, 
CHCH2CH(CH3)2), 7.95 (1H, d, NH), 8.19 (1H, t, ArH), 8.30 (1H, t, ArH), 9.18 (1H, d, 
NH). 13C NMR (75 MHz, CD3OD) 18.3 (CH3), 19.6 (CH3), 22.1, 22.8 (CH3), 24.8 
(CHCH2CH(CH3)2), 30.5 (CHCH(CH3)2), 30.9 (CH(CH3)2), 39.8 (CHCH2CH(CH3)2), 
50.3 (CHCH2OH), 52.9 , 59.7 (CHCH(CH3)2), 65.6 (CH2OH), 76.5 (OCH3), 77.0, 77.4, 
125.7 (CHCHCH), 127.5 (CHCHCH), 138.6 (CHCHCH), 146.7 (CHCCO), 149.3 
(CHCCO), 164.2 (CONH), 171.5 (CONH), 207.0 (CONH); m/z (ES) [M+(H)]+ 381 
(30%); [M+Na]
 + 402 (25%).  
73
{4-[(S)-1-((S)-1-Hydroxymethyl-3-methyl-butylcarbamoyl)-2-methyl- 
propylcarbamoyl]-phenyl}-carbamic acid tert-butyl ester (31c) 
H
NO
O
H
N
O
N
H
O
OH
The aminobenzoic acid 18 (768 mg, 3.24 mmol) and ammonium salt 29 were coupled by 
the general procedure A1. The crude product was purified by flash column 
chromatography over silica gel using ethyl acetate - petroleum ether (1:1) as eluent to 
give 31c as a white solid (916mg, 65%). Rf=0.34; H (CD3OD) 0.86-0.92 (6H, m, 
(CH3)2), 1.03 (6H, d, (CH3)2), 1.40 (2H, m, CHCH2CH(CH3)2), 1.50 (9H, s, (CH3)3) 
2.17-2.21 (1H, m, CHCH2CH(CH3)2), 3.30 (1H, m, CHCH(CH3)2), 3.45 (2H, m, 
CH2OH), 4.25 (1H, t, CHCH(CH3)2), 7.50 ( 2H, d, 2ArH), 7.75 (2H, d, 2ArH), 7.79 (1H, 
d, NH Val), 8.01 ( 1H, d, NH, Leu), 9.17 (1H, s, NH). 13C NMR (75 MHz, CD3OD) 13.4 
(CHCH3), 18.2 (CHCH3), 18.8 (CHCH3), 19.8 (CCH3), 21.2 (CCH3), 22.7 (CCH3), 24.8 
(CHCH2CH(CH3)2), 27.6 (CHCH(CH3)2), 30.8 (CHCH(CH3)2), 40.0 (CHCH2CH(CH3)2), 
48.8 (CH2OH), 49.7 (C(CH3)3), 60.2 (CHCH2CH(CH3)2), 64.6 (CHCH(CH3)2), 117.7 
(CHCHC), 127.8 (CHCHC), 128.3 (CHCHC), 143.2 (CHCHC), 153.5 (BocCO), 168.7 
(CONH), 172.0 (CONH). m/z (ES) [M+(H)]+ 436 (50%); [M+Na]
 + 457 (30%). 
N-[(S)-1-((S)-1-Hydroxymethyl-3-methyl-butylcarbamoyl)-2-methyl-propyl]- 
nicotinamide (31d) 
H
N
O
N
H
O
OH
N
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Nicotinic acid 30d (253.3mg, 2.057mmol) was reacted with ammonium salt 29 using 
general procedure A3 to give 31d as a white solid (430mg, 68%). mp 136-138oC; Rf=0.51; 
H (CD3OD) 0.87 (3H, d, CH3), 0.89 (3H, d, CH3), 1.02 (6H, d, (CH3)2), 1.35–1.45 (2H, 
m, CHCH2CH(CH3)2), 1.63 (1H, m, CHCH2CH(CH3)2), 2.19 (1H, m, CHCH(CH3)2), 
3.47 (2H, t, CH2OH), 4.02 (1H, m, CHCH(CH3)2), 4.35 ( 1H, d, CHCH2CH(CH3)2), 7.51 
( 1H, t, ArH), 8.22 (1H, d, NH), 8.85 (1H, d, NH), 8.96 ( 1H, s, ArH). 13C NMR (75 
MHz, CD3OD) 13.1 (CH3), 17.8 (CH3), 20.8 (CH3), 22.4 (CH3), 24.5 
(CHCH2CH(CH3)2), 30.3 (CHCH(CH3)2), 39.7 (CHCH2CH(CH3)2), 51.4 
(CHCH2CH(CH3)2), 60.1 (CHCH(CH3)2), 64.2 (CH2OH), 123.7 (CHCHCHC), 130.6 
(CHCHCHC), 135.8 (CHCHCHC), 147.9 (CHCHN), 151.3 (CCHN), 166.6 (CONH), 
171.9 (CONH); m/z (ES) [M+(H)]+ 323 (55%); [M+Na]
 + 344 (30%).  
5-Formyl-furan-2-carboxylic acid {1-[(S)-1-((S)-hydroxymethyl)-3-methyl-butyl 
carbamoyl]-2-methylpropyl}-amide (31e) 
H
N
O
N
H
O
OH
O
H
O
5-Formyl-furan-2-carboxylic acid 30e (277.1mg, 1.98mmol) was reacted with 
ammonium salt 29 using the general procedure A3. The crude product was purified with 
flash column chromatography over silica gel with ethyl acetate - petroleum ether (4:1) as 
eluent to give 31e as a white solid (198 mg, 31%). Rf=0.21; νmax (KBr) 1638 (C=ONH), 
1038 (C-OH); H (DMSO) 0.77-0.86 (12H, m, (CH3)4), 1.25 (2H, m, CHCH2CH(CH3)2), 
1.58 (1H, m, CHCH2CH(CH3)2), 2.03 (1H, m, CHCH(CH3)2), 3.20 (1H, m, CH2OH), 
3.29 (1H, m, CH2OH), 3.79 (1H, m, CHCH(CH3)2), 4.0 (1H, m, CHCH2CH(CH3)2). 7.40 
(1H, m, ArH), 7.58 (1H, d, ArH), 7.80 (1H, d, NH), 8.39(H, d, NH), 9.67 (1H, s, CHO). 
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13C NMR (75 MHz, CDCl3) 18.9 (CH3), 19.1 (CH3), 22.4 (CH3), 22.8 (CH3), 24.9 
(CHCH(CH3)2), 40.0 (CHCH2CH(CH3)2), 48.6 (CHCH2CH(CH3)2), 58.4 (CHCH(CH3)2), 
64.8 (CH2OH), 110.7 (CHCCHO), 122.0 (CHCCO), 132.3 (CHCCHO), 133.6 (CHCCO), 
159.5 (CONH), 171.0 (CONH), 181.0 (CHO). HRMS (ES+) calcd for C17H27N3O4 
(M+H+) 338.2080 found 338.2086. 
N-[1-((S)-1-Hydroxymethyl-3-methyl-butylcarbamoyl)-2-methyl-propyl]- 
2,4,6-trimethoxy-benzamide (31f) 
OO
O
H
N
O
N
H
O
OH
2,4,6-Trimethoxy-benzoic acid 30f (420mg, 1.978mmol), was reacted with ammonium 
salt 29 using general procedure A3. The crude product was purified with flash column 
chromatography over silica gel using MeOH/DCM (5%) to give 31f as a white solid (613 
mg, 76%). mp 188-190oC. Rf=0.25; H (DMSO) 0.90 (6H, m, (CH3)2), 1.07 (6H, m, 
(CH3)2), 1.41 (2H, m, CHCH2CH(CH3)2), 1.70 (1H, m, CHCH2CH(CH3)2), 2.21 (1H, m, 
CHCH(CH3)2), 3.50 (2H, t, CH2OH), 3.85 (3H, s, OCH3), 3.92 ( 6H, s, O(CH3)2), 4.02 
( 1H, m, CHCH2CH(CH3)2), 4.37 (1H, d, CHCH(CH3)2), 7.23 (2H, s, 2ArH), 8.45 (1H, d, 
NH), 8.75( 1H, d, NH). 13C NMR (75 MHz, CD3OD) 18.2 (CH3), 18.7 (CH3), 21.1 
(CH3), 22.6 (CH3), 24.7 (CHCH(CH3)2), 40.0 (CHCH2CH(CH3)2), 48.1 
(CHCH2CH(CH3)2), 49.7 (CHCH(CH3)2), 55.6 (CH3O), 60.0 (CH3O), 60.4 (CH3O), 64.4 
(CH2OH), 97.0 (CHCCH) , 105.0 (CHCCH), 129.6 (CH3OC), 153.3 (CH3OC), 159.6 
(CH3OC), 168.5 (CONH), 172.6, (CONH). (Found C, 61.65; H, 8.44; N, 6.82% 
C21H34N2O6 requires C, 61.44; H, 8.35; N, 6.82%). m/z (ES) [M+(H)]
+ 412 (50%); [M+Na]
+ 432 (25%). 
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4-Formyl-1H-pyrrole-2-carboxylic acid {1-[(S)-1-((S)-hydroxymethyl)-3-methyl- 
butyl-carbamoyl]-2-methyl-propyl}-amide (31g) 
H
N
O
N
H
O
OH
N
H
O
H
4-Formyl-1H-pyrrole-2-carboxylic acid 19 (275mg, 1.98 mmol) was reacted with 
ammonium salt 29 using general procedure A3. The crude product was purified with flash 
column chromatography over silica gel using ethyl acetate - petroleum ether (4:1) as 
eluent to give 31g as a white solid (236 mg, 36%). mp 112-115oC; Rf=0.30; HRMS (ES+) 
calcd for C17H27N3O4 (M+H
+) 338.2080 found 338.2066; νmax (KBr) 1624 (C=ONH), 
1038 (C-OH); H (DMSO) 0.85-0.90 (12H, m, (CH3)4), 1.27-1.31 (2H, m, 
CHCH2CH(CH3)2), 1.60 (1H, m, CHCH2CH(CH3)2), 2.09 (1H, m, CHCH(CH3)2), 3.35 
(2H, t, CH2OH), 3.82 (1H, m, CHCH(CH3)2), 4.22 ( 1H, t, CHCH2CH(CH3)2), 7.41 ( 1H, 
s, ArH), 7.65 (1H, d, NH), 7.70 (1H, s, ArH), 8.14 (1H, d, NH), 9.74 (1H, s, CHO), 
12.33 (1H, s, NH, Pyrrole) 13C NMR (75 MHz, (DMSO) 19.5 (CH3), 20.0 (CH3), 22.5 
(CH3), 24.1 (CH3), 24.8 (CHCH2CH(CH3)2), 32.2 (CHCH(CH3)2), 41.1 
(CHCH2CH(CH3)2), 49.4 (CH2OH), 59.3 (CHCH2CH(CH3)2), 64.6 (CHCH(CH3)2), 
109.5 (CHCH), 127.1, (CHCCHO), 129.2 (CCONH), 130.9 (CN), 160.6 (CONH), 171.3 
(CONH), 186.6 (CCHO); m/z (ES) ([M+(H)]+, 338 (10%),  (Found C, 59.12; H, 8.01; N, 
12.04% C17H27N3O4 .0.67H2O requires C, 58.94; H, 8.15; N, 12.13%). ([M+(Na)]+, 360 
(100%). 
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1H-Indole-2-carboxylic acid [(S)-1-((S)-1-hydroxymethyl-3-methyl- 
butylcarbamoyl)-2-methyl-propyl]-amide (31i) 
H
N
O
N
H
O
OH
N
H
Indole-2-carboxylic acid 30i (319mg, 1.98 mmol) was reacted with ammonium salt 29
using general procedure A3. The crude product was purified by flash column 
chromatography over silica gel using ethyl acetate - petroleum ether (1:1) as eluent to 
give 31i as a white solid (497mg, 70%). mp 61-63oC; Rf=0.17; H (CD3OD) 0.89-0.91 
(6H, m, (CH3)2), 1.06-1.08 (6H, m, (CH3)2, 1.41 (2H, m, CHCH2CH(CH3)2), 1.65 (1H, m, 
CHCH2CH(CH3)2), 2.20 (1H, m, CHCH(CH3)2), 3.56 (2H, t, CH2OH), 4.06 (1H, m, 
CHCH2CH(CH3)2), 4.41 ( 1H, m, CHCH(CH3)2), 7.09 ( 2H, t, 2ArH), 7.21 (2H, t, 2ArH), 
7.43 (1H, d, NH), 7.65 (1H, d, NH), 8.08 (1H, d, NH). 13C NMR (75 MHz, CDCl3) 19.5 
(CH3), 20.0 (CH3), 22.5 (CH3), 24.1 (CH3), 24.9 (CHCH(CH3)2), 40.2 
(CHCH2CH(CH3)2), 49.4 (CHCH2CH(CH3)2), 59.3 (CHCH(CH3)2), 64.5 (CH2OH), 
104.3 (NHCCHCH), 112.2 (NHCCHCHCH), 120.4 (CCHCH), 124.1 (NHCCH), 127.7 
(NHCC), 132.0 (NHCC), 137.2 (NHCCH), 161.5 (CONH), 171.3 (CONH). (Found C, 
66.64; H, 8.03; N, 11.51% C20H29N3O3 requires C, 66.83; H, 8.13; N, 11.69%). HRMS 
(E+S) calc for C17H25N3O3 ([M+H]
+) 360.2287 found 360.2271. 
(S)-N-((S)-1-Formyl-3-methyl-butyl)-3-methyl-2-(2-pyridin-2-yl-acetylamino)- 
butyramide (33a) 
N
H
N
O
N
H
O
O
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Alcohol 31a (170 mg, 0.5 mmol) was oxidised using general procedure B. The crude 
product was purified by flash column chromatography over silica gel using MeOH -   
DCM (5%) as eluent to give 33a as a white solid (84 mg, 45%). mp 116-118oC; Rf= 0.34; 
H (DMSO) 0.82-0.88 (12H, m, (CH3)4), 1.51-1.60 (3H, m, CHCH2CH(CH3)2 and 
CHCH2CH(CH3)2), 2.04 (1H, m, CHCH(CH3)2), 3.70 (2H, s, CH2CO), 4.12 ( 1H, m, 
CHCH(CH3)2), 4.21 ( 2H, t, CHCH2CH(CH3)2), 7.21 ( 1H, t, ArH), 7.25 (1H, d, NH), 
7.75 (1H, t, ArH), 8.21( 2H, d, NH), 8.43 ( 2H, t, 2ArH), 9.38 (1H, s, CHO). 13C NMR 
(75 MHz, CD3OD) 18.0 (CH3), 19.2 (CH3), 21.3 (CH3), 23.1 (CH3), 24.0 
(CHCH2CH(CH3)2), 30.4 (CHCH(CH3)2), 36.2 (CHCH2CH(CH3)2), 39.6 (CH2CO), 56.7 
(CHCH2CH(CH3)2), 57.6 (CHCH(CH3)2), 121.7 (CHCHCHCH), 123.6 (CHCHCHCH), 
136.5 (CHCHCHCH), 147.6 (NCHCH), 156.5 (NCCH), 169.1 (CONH), 171.1 (CONH), 
201.1 (CHCHO). m/z (ES) [M+(H)]+ 334 (50%). 
6-[(S)-1-((S)-1-Formyl-3-methyl-butylcarbamoyl)-2-methyl-propylcarbamoyl]- 
pyridine-2-carboxylic acid methyl ester (33b) 
N
O
O
H
N
O
N
H
O
O
Alcohol 31b (400 mg, 1.06 mmol) was oxidised using general procedure B. The crude 
product was purified by flash column chromatography over silica gel using ethyl acetate - 
petroleum ether (1:2 - 1:1) as eluent to give 33b as a white solid (193mg, 49%). Rf=0.43; 
H (DMSO) 0.82-0.95 (12H, m, (CH3)4), 1.30–1.40 (2H, m, CHCH2CH(CH3)2), 1.60 
(1H, m, CHCH2CH(CH3)2), 2.12 (1H, m, CHCH(CH3)2), 3.92 (3 H, s, COOCH3), 4.20 
(1H, m, CHCH(CH3)2), 4.52 ( 1H, m, CHCH2CH(CH3)2), 8.23-8.28 (3H, m, ArH), 8.42 
(1H, d, NH Val), 8.67 (1H, d, NH Leu), 9.43 (1H, s, CHO). 13C NMR (75 MHz, CD3OD) 
18.3 (CH3), 19.4 (CH3), 22.1 (CH3), 22.8 (CH3), 24.8 (CHCH2CH(CH3)2), 30.5 
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(CHCH(CH3)2), 36.9 (CHCH2CH(CH3)2), 50.3 (CH3O), 52.9 (CHCH2CH(CH3)2), 59.6 
(CHCH(CH3)2), 125.4 (CHCHCH), 127.5 (CHCHCH), 138.6 (CHCHCH), 146.7 (CN), 
149.3 (CN), 162.6 (CONH), 164.4 (CONH), 169.3 (COOCH3) 201.0 (CHCHO); m/z (ES) 
[M+(H)]+ 379 (20%); [M+Na]
 + 395 (15%).  
{4-[(S)-1-((S)-1-Formyl-3-methyl-butylcarbamoyl)-2-methyl-propylcarbamoyl]- 
pheyl}-carbamic acid tert-butyl ester (33c) 
H
NO
O
H
N
O
N
H
O
O
Alcohol 31c (194 mg, 445 mmol) was oxidised using general procedure B. The crude 
product was purified by flash column chromatography over silica gel using ethyl acetate - 
petroleum ether (1:2-1:1) as eluent to give 33c as a white solid (110 mg, 57%). Rf=0.45; 
H (DMSO) 0.75-0.85 (12H, m, (CH3)4), 1.21-1.30 (9H, m, C(CH3)3), 1.55 (1H, m, 
CHCH2CH(CH3)2), 2.04-2.07 (1H, m, CHCH(CH3)2), 3.19 (1H, m, CHCH(CH3)2, 4.21 
(1H, t, CHCH(CH3)2), 7.50 ( 2H, d, 2ArH), 7.59 (1H, d, NH Val), 7.78 (2H, d, 2ArH), 
7.97( 1H, d, NH) 9.59 ( 1H, s, CHO). 13C NMR (75 MHz, CDCl3) 18.8 (CHCH3), 19.3 
(CHCH3), 21.3 (CHCH3), 21.8 (CHCH3), 23.0 (CCH3), 23.4 (CCH3), 24.0 (CCH3), 24.1 
(CHCH2CH(CH3)2), 28.1 (CHCH(CH3)2), 36.3 (CHCH2CH(CH3)2), 56.8  (C(CH3)3), 
59.0 (CHCH2CH(CH3)2), 63.8  (CHCH(CH3)2), 117.0 (CHCHC), 127.5 (CHCHC), 
127.6 (CHCHC), 128.3 (CHCHC), 128.4 (CCHCHC), 142.3 (CHCHC), 152.6 (BocCO), 
165.8 (CONH), 170.7 (CONH), 201.2 (CHO). 
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N-[(S)-1-((S)-1-Formyl-3-methyl-butylcarbamoyl)-2-methyl-propyl]-nicotinamide 
(33d) 
H
N
O
N
H
O
O
N
Alcohol 31d (200mg, 0.622mmol) was oxidised using general procedure B to afford the 
product 33d as a grey solid (119mg, 61%). mp 85-87oC. H (DMSO) 0.80-0.93 (12H. m, 
(CH3)4), 1.30-1.45 (2H, m, CHCH2CH(CH3)2), 1.63 (1H, m, CHCH2CH(CH3)2), 2.10 
(1H, m, CHCH(CH3)2), 4.02 (1H, m, CHCH(CH3)2), 4.35 (1H, t, CHCH2CH(CH3)2), 
7.51 ( 1H, t, ArH), 8.22 (1H, d, NH), 8.45 (1H, d, NH), 8.59 (1H, d, ArH), 8.70 (1H, m, 
ArH), 8.98 (1H, s, ArH), 9.40 (1H, s, CHO) 13C NMR (75 MHz, CD3OD) 18.7 (CH3), 
19.3 (CH3), 21.3 (CH3), 23.0 (CH3), 24.0 (CHCH2CH(CH3)2), 30.1 (CHCH(CH3)2), 39.7 
(CHCH2CH(CH3)2), 56.8 (CHCH2CH(CH3)2), 59.2 (CHCH(CH3)2), 123.4 (CHCHCHC), 
129.8 (CHCHCHC), 135.3 (CHCHCHC), 148.6 (CHCHN), 151.9 (CCHN), 165.3 
(CONH), 171.5 (CONH), 201.2 (CCHO); (Found C, 61.23; H, 7.94; N, 12.41% 
C17H25N3O3 .0.67H2O requires C, 61.61; H, 8.01; N, 12.68%). m/z (ES) [M+(H)]
+ 320 
(50%).   
5-Formyl-furan-2-carboxylicacid [1-((S)-(S)-1-formyl-3-methyl-butylcarbamoyl) 
-2-methyl-propyl]-amide (33e) 
H
N
O
N
H
O
O
O
H
O
Alcohol 31e (152mg, 0.45mmol) was oxidized using general procedure B to give 33e as a 
white solid (135mg, 88%). mp 70-72 ºC; Rf = 0.28 (EtOAc / petroleum ether [1:1]); 
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HRMS (ES+) calcd for C17H25N3O4 (M+H
+) 336.1923 found 336.1925; νmax (KBr) 1738 
(CHO), 1636 (CONH); 1H NMR (500 MHz, CDCl3) 0.79 (3H, d, J 7, CH3), 0.82 (3H, d, 
J 7, CH3), 1.01 (3H, d, J 7, CH3), 1.06 (3H, d, J 7, CH3),  1.23-1.26 (1H, m, 
CH2CH(CH3)2), 1.63-1.653 (2H, m, CH2CH(CH3)2), 2.01-2.03 (1H, m, CH(CH3)2), 
4.02-4.04 (1H, m, CHCH2CH(CH3)2), 4.80 (1H, t, J 8, CHCH(CH3)2), 6.84-6.88 (1H, m, 
CHCH), 6.93-6.95 (1H, m, CHCCHO), 7.75 (1H, d, J 7, NH), 7.82 (1H, d, J 7, NH), 
9.58 (1H, s, CHO), 9.60 (1H, s, CHO), 11.82 (1H, br s, NHpyrrole); 
13C NMR (75 MHz, 
CDCl3) 18.9 (CH3), 19.2 (CH3), 21.63 (CH3), 22.8 (CH3), 24.6 (CHCH2CH(CH3)2), 30.8 
(CHCH(CH3)2), 37.2 (CHCH2CH(CH3)2), 57.5 (CHCH2CH(CH3)2), 59.1 (CHCH(CH3)2), 
111.9 (CHCH), 121.1, (CHCCHO), 132.2 (CCONH), 134.2 (CN), 160.1 (CONH), 172.5 
(CONH), 180.6 (CCHO), 199.5 (CHCHO); m/z (ES) ([M+(H)]+, 336 (100%); 
([M+(Na)]+  358 (10%).  
4-Formyl-1H-pyrrole-2-carboxylic acid [1-((S)-(S)-1-formyl-3-methyl-butyl 
carbamoyl)-2-methyl-propyl]-amide (33g) 
H
N
O
N
H
O
O
N
H
O
H
The alcohol 31g (236.5mg, 0.372mmol) was oxidized using general procedure B to 
afford product 33g as a white solid (135mg, 88%). mp 101-103oC; νmax (KBr) 1736 
(CHO), 1643 (CONH); 1H NMR (500 MHz, (CD3)2SO) 0.82 (3H, d, J=6.5 Hz, CH3), 
0.86 (3H, d, J=6.0 Hz, CH3), 0.90 (3H, d, J=7.0 Hz, CH3), 1.06 (3H, d, J=7.5 Hz, CH3),  
1.41-1.44 (1H, m, CH2CH(CH3)2), 1.50-1.56 (1H, m, CH2CH(CH3)2), 1.61-1.65 (1H, m, 
CH2CH(CH3)2), 2.05-2.11 (1H, m, CH(CH3)2), 4.10-4.14 (1H, m, CHCH2CH(CH3)2), 
4.30 (1H, t, J=8.5 Hz, CHCH(CH3)2), 7.41 (1H, s, CHCH), 7.69 (1H, s, CHCCHO), 8.17 
(1H, d, J=9.0 Hz, NH), 8.42 (1H, d, J=7.5 Hz, NH), 9.38 (1H, s, CHO), 9.72 (1H, s, 
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CHO), 12.30 (1H, br s, NHpyrrole); 
13C NMR (75 MHz, DMSO) 18.7 (CH3), 19.4 (CH3), 
21.6 (CH3), 23.8 (CH3), 24.1 (CHCH2CH(CH3)2), 30.0 (CHCH(CH3)2), 36.2 
(CHCH2CH(CH3)2), 58.3 (CHCH2CH(CH3)2), 59.8 (CHCH(CH3)2), 119.0 (CHCH), 
126.5, (CHCCHO), 128.3 (CCONH), 130.3 (CN), 160.0 (CONH), 171.7 (CONH), 185.9 
(CCHO) 201.2 (CHCHO); m/z (ES) [M+(H)]+  336 (100%). (Found C, 58.67; H, 7.46; N, 
11.90% C17H25N3O4.0.67H2O requires C, 58.77; H, 7.64; N, 12.10%). HRMS (ES+) calcd 
for C17H25N3O4 (M+H
+) 336.1923 found 336.1934. 
1H-Indole-2-carboxylic-acid[(S)-1-((S)-1-formyl-3-methyl-butyl-carbamoyl)-2- 
methyl-propyl]-amide (33i) 
H
N
O
N
H
O
O
N
H
The alcohol 31i (116mg, 323mmol) was oxidised using general procedure B to afford 
product 33i as a white solid (93mg, 81%). mp 96-98oC; H (DMSO) 0.82 (3H, d, CH3), 
0.84 (3H, d, CH3), 0.87 (3H, d,CH3), 0.89 (3H, d, CH3), 1.30 (2H, m, CHCH2CH(CH3)2), 
1.61 (1H, m, CHCH2CH(CH3)2), 2.01 (1H, m, CHCH(CH3)2), 4.03 (1H, t, 
CHCH2CH(CH3)2), 4.21 ( 1H, d, CHCH(CH3)2), 7.06 ( 1H, t, ArH), 7.20 (1H, t, ArH), 
7.31 (1H, s, ArH), 7.44( 1H, d, NH), 7.62 ( 1H, d, NH), 7.74 (1H, d, ArH), 8.26 (1H, d, 
ArH), 11.6 (1H, s, CHO). 13C NMR (75 MHz, DMSO) 19.5 (CH3), 20.0 (CH3), 22.5 
(CH3), 24.1 (CH3), 24.9 (CHCH(CH3)2), 40.2 (CHCH2CH(CH3)2), 49.4 
(CHCH2CH(CH3)2), 59.3 (CHCH(CH3)2), 64.5 (CH2OH), 104.3 (NHCCHCH), 112.2 
(NHCCHCHCH), 120.4 (CCHCH), 124.1 (NHCCH), 127.7 (NHCC), 132.0 (NHCC), 
137.2 (NHCCH), 161.5 (CONH), 171.3 (CONH). (Found C, 65.37; H, 7.93; N, 11.24% 
C17H25N3O3 .0.5H2O requires C, 65.55; H, 7.76; N, 11.47%). HRMS (E+S) calc for 
C20H27N3O3 ([M+H]
+) 358.2052 found 358.2037.   
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4-Amino-N-[(S)-1-((S)-1-formyl-3-methyl-butylcarbamoyl)-2-methyl-propyl]- 
benzamide hydrochloride salt (35) 
H
N
O
N
H
O
HCl.H2N
O
Compound 33c (20 mg) was dissolved in HCl -dioxane (4M, 1ml) and the solution was 
stirred overnight. The solvent was removed on a rotary evaporator under vacuum to give 
product 35 as a yellow oil (17 mg, 98%). The product was used in the subsequent 
reaction without further purification. 
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APPENDIX: ASSAY DATA 
The assays were carried out by Janna Nikkel, a graduate student at Canterbury, using 
Lincoln University’s facilities and with advice from Dr Jim Morton and his students and 
Dr Matthew Jones, a Post-doctoral Fellow in the group working at Canterbury.  
The assay protocol used in this thesis was based on the protocol of Thompson et al1 and 
makes use of casein, a water soluble protein, labeled with the fluorophore 
4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propanoic acid (BODIPY).  
Compounds 33a-k were assayed against m-calpain and their inhibition constant (IC50) 
value determined.  
The solution of m-calpain was produced by Dr Jim Morton.  
The assays were performed in 96-well black Whatman plates.  
Two blank control assays were utilized;  
Calcium blank: 100 L of 100 mM calcium chloride,  
  
Addition of BODIPY-casein to this blank results in no reaction and thereby provides the 
base line for the fluorometer. 
EDTA blank: 25 L of 10 mM EDTA solution diluted with 25 L distilled water and 50 
L of the enzyme in sample buffer (20 mM TRIS-HCl, pH 7.5 containing 1 mM EDTA, 1 
mM EGTA, and 2 mM mM TRIS-HCl, pH 7.5 containing 1 mM EDTA, 1 mM EGTA, 
and 2 mM dithiothreitol)    
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Addition of BODIPY-casein to this blank results in no reaction since the calcium ions are 
bound to the EDTA, thus the m-calpain cannot be activated.  This confirms the base line 
in the fluorometer. 
The assay: 
Calpain activity control assay: 50 L m-calpain in sample buffer (20 mM TRIS-HCl, 
pH 7.5 containing 1 mM EDTA, 1 mM EGTA, and 2 mM dithiothreitol) diluted with 50 
L distilled water.  
The inhibitor assay: 50 L m-calpain and 50 L of inhibitor (of known concentration) 
diluted in distilled water.  
The reaction of m-calpain and BODIPY-casein in both the presence and absence of 
inhibitor was initiated by the addition 100 µL of BODIPY-casein substrate solution to 
each well at 25 °C.  The progress of each reaction was followed for 10 min in an 
automated BMG Fluostar fluorometer with excitation of 485 nm and measuring emission 
of 530 nm.  
The percentage inhibition was determined as the percentage of the m-calpain activity 
with inhibitor present compared with the activity of the control m-calpain activity assay.  
Assays were performed in triplicate with serial dilutions of inhibitor concentrations from 
50 µM to 50 nM.  
Concentrated BODIPY-casein was supplied by Lincoln University. A fresh batch of the 
diluted BODIPY-casein substrate solution was prepared for each assay. The BODIPY 
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casein substrate solution comprises: digestion buffer (500 L) (prepared from 2ml 100 
mM tris(hydroxymethyl)methylamine and 2 ml 10 mM sodium azide, adjusted to a pH 
7.8 by the addition of 10 mM sodium hydroxide and the solution diluted to a volume of 
10 ml with water) deionized water (8440 L), 100 mM CaCl2 (1000 L), BODIPY-casein 
(50 L) and -mercaptoethanol (10 L).  
The stock solutions of inhibitor were prepared as 1 mM solutions in DMSO. Further 
dilutions by the addition of distilled water gave the range of concentrations: 50, 10, 2, 0.4, 
0.2, 0.1 and 0.05 M for inhibition assay.  
The percent inhibition of m-calpain for each compound was calculated based on the 
average change in fluorescence70; the assay data obtained was plotted on a graph as 
percentage inhibition versus the log of inhibitor concentration. IC50 was then determined 
as shown in Figure 30. 
y = 23.535x + 37.014
R
2
 = 0.9686
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250 2.4 88.8 
125 2.1 86.0 
62.5 1.8 81.4 
31.25 1.5 76.8 
6.25 0.8 60.1 
1.25 0.1 37.5 
0.25 -0.6 12.2 
0.05 -1.3 12.9 
Figure 30: Linear inhibition date for 33b. The percentage inhibition was plotted against 
the log value of inhibitor concentration. The linear best fit was obtained and the IC50
value was calculated using the equation for the line of best fit. The corresponding log 
value was converted back to units of concentration (3.56 M).  
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